Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study With a Safety lead-in Cohort and Expansion Phase, of the Safety, Tolerability, Biological Effect, and Efficacy of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer

Next Previous
Search
Trial Profile

A Phase Ib Study With a Safety lead-in Cohort and Expansion Phase, of the Safety, Tolerability, Biological Effect, and Efficacy of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; Natural killer cell therapies (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; HER2 positive breast cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms NK-ACT-BC_2020

    • Most Recent Events

    • 14 Mar 2025 According to ClinicalTrials.gov: US National Institutes of Health, Elena Garralda, MD,Vall d'Hebron Institute of Oncology and Ignacio Melero, MD,Clinica Universidad de Navarra are the Principal Investigator of the study.
    • 14 Mar 2025 New trial record
    • 13 Dec 2024 Trial design presented at the 47th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top